What question did this study set out to answer?

To evaluate the clinical and microbiological efficacy of empiric trimethoprim-sulfamethoxazole (TMP-SMX) in treating uncomplicated urinary tract infections caused by TMP-SMX-resistant uropathogens in a high-prevalence area.

May 1, 2002Clinical Infectious Diseases

Empiric Use of Trimethoprim‐Sulfamethoxazole (TMP‐SMX) in the Treatment of Women with Uncomplicated Urinary Tract Infections, in a Geographical Area with a High Prevalence of TMP‐SMX–Resistant Uropathogens

View Full Paper

Ask AI

Bookmark

Authors

RRRaanan RazHebrew University of Jerusalem BCBibiana ChazanTechnion – Israel Institute of Technology YKYoram KennesTel Aviv University

Discussion

Member takes

Implication

Prospective study demonstrates significantly lower cure rates with empiric trimethoprim-sulfamethoxazole in women with resistant urinary tract infections, indicating it should not be standard therapy.

Key Points

To evaluate the clinical and microbiological efficacy of empiric trimethoprim-sulfamethoxazole (TMP-SMX) in treating uncomplicated urinary tract infections caused by TMP-SMX-resistant uropathogens in a high-prevalence area.
Prescribed empiric TMP-SMX to healthy, nonpregnant premenopausal women presenting with symptomatic uncomplicated lower UTI confirmed by pyuria or bacteriuria.
Obtained baseline urine cultures and assessed microbiological and clinical cure at days 5–9 (visit 2) and days 28–42 (visit 3) following therapy completion.
Baseline urine cultures yielded 71% TMP-SMX-susceptible (TMP-SMX-S) and 29% TMP-SMX-resistant (TMP-SMX-R) uropathogens, with Escherichia coli remaining the predominant pathogen in both cohorts.
Microbiological cure at days 5–9 was achieved in 86% of patients with TMP-SMX-S infections compared with 42% of patients with TMP-SMX-R infections.
Clinical evaluations at days 28–42 confirmed persistent differences in treatment success between the susceptible and resistant groups.

Cite This Study

Raz et al. (2002) studied this question.

synapsesocial.com/papers/6a7cc5800bb6134e42cf8555 https://doi.org/10.1086/339812

View Full Paper

Ask AI

Bookmark

Empiric Use of Trimethoprim‐Sulfamethoxazole (TMP‐SMX) in the Treatment of Women with Uncomplicated Urinary Tract Infections, in a Geographical Area with a High Prevalence of TMP‐SMX–Resistant Uropathogens

Discussion

Member takes

Implication

Key Points

Cite This Study

Empiric Use of Trimethoprim‐Sulfamethoxazole (TMP‐SMX) in the Treatment of Women with Uncomplicated Urinary Tract Infections, in a Geographical Area with a High Prevalence of TMP‐SMX–Resistant Uropathogens

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider